Shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the company. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.25.

Several research analysts recently weighed in on SGMO shares. Cowen and Company restated a “buy” rating on shares of Sangamo BioSciences in a research report on Wednesday, August 10th. Jefferies Group restated a “buy” rating on shares of Sangamo BioSciences in a research report on Friday, August 5th. Zacks Investment Research upgraded shares of Sangamo BioSciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 20th. Janney Montgomery Scott downgraded shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $15.00 to $8.00 in a research report on Thursday, August 4th. Finally, Piper Jaffray Cos. cut shares of Sangamo BioSciences from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $5.00 in a research note on Wednesday, October 19th.

Shares of Sangamo BioSciences (NASDAQ:SGMO) traded down 1.43% during mid-day trading on Monday, reaching $3.45. 551,479 shares of the company’s stock traded hands. Sangamo BioSciences has a 12-month low of $3.10 and a 12-month high of $9.91. The company’s 50-day moving average price is $3.87 and its 200-day moving average price is $5.07. The stock’s market capitalization is $243.65 million.

Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, October 26th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.02. Sangamo BioSciences had a negative return on equity of 45.02% and a negative net margin of 388.23%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $4.24 million. During the same quarter last year, the company earned ($0.13) EPS. The firm’s revenue for the quarter was down 67.1% on a year-over-year basis. Analysts anticipate that Sangamo BioSciences will post ($1.14) earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers boosted its stake in Sangamo BioSciences by 7.4% in the second quarter. Rhumbline Advisers now owns 77,773 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 5,370 shares during the period. Teachers Advisors Inc. boosted its stake in Sangamo BioSciences by 0.4% in the second quarter. Teachers Advisors Inc. now owns 157,035 shares of the biopharmaceutical company’s stock valued at $909,000 after buying an additional 610 shares during the period. Janney Montgomery Scott LLC boosted its stake in Sangamo BioSciences by 88.5% in the second quarter. Janney Montgomery Scott LLC now owns 29,556 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 13,878 shares during the period. BlackRock Fund Advisors boosted its stake in Sangamo BioSciences by 5.6% in the second quarter. BlackRock Fund Advisors now owns 2,713,404 shares of the biopharmaceutical company’s stock valued at $15,711,000 after buying an additional 145,060 shares during the period. Finally, BlackRock Investment Management LLC boosted its stake in Sangamo BioSciences by 17.4% in the second quarter. BlackRock Investment Management LLC now owns 275,923 shares of the biopharmaceutical company’s stock valued at $1,598,000 after buying an additional 40,923 shares during the period. 62.24% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Sangamo BioSciences Inc. (SGMO) Given Average Recommendation of “Hold” by Brokerages” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/28/sangamo-biosciences-inc-sgmo-given-average-recommendation-of-hold-by-brokerages.html.

Sangamo BioSciences Company Profile

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

5 Day Chart for NASDAQ:SGMO

Receive News & Stock Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related stocks with our FREE daily email newsletter.